scholarly journals Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis

Cancer ◽  
2000 ◽  
Vol 88 (11) ◽  
pp. 2512-2519 ◽  
Author(s):  
Annie C. Beaujard ◽  
Olivier Glehen ◽  
Jean L. Caillot ◽  
Yves Francois ◽  
Jacques Bienvenu ◽  
...  
Keyword(s):  
Peritoneal Carcinomatosis ◽  
Cancer Patients ◽  
Digestive Tract ◽  
Mitomycin C ◽  
Digestive Tract Cancer ◽  
Tract Cancer

scholarly journals Effect of Vitamin D Supplementation on Survival of Digestive Tract Cancer Patients with Low Bioavailable 25-Hydroxyvitamin D Levels: A Post Hoc Analysis of the AMATERASU Randomized Clinical Trial

Cancers ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 347 ◽  
Author(s):  
Mitsuyoshi Urashima ◽  
Mai Okuyama ◽  
Taisuke Akutsu ◽  
Hironori Ohdaira ◽  
Mutsumi Kaji ◽  
...  
Keyword(s):  
Vitamin D ◽  
Cancer Patients ◽  
Digestive Tract ◽  
Vitamin D Supplementation ◽  
Digestive Tract Cancer ◽  
Post Hoc Analysis ◽  
Hydroxyvitamin D ◽  
Tract Cancer ◽  
25 Hydroxyvitamin D ◽  
Post Hoc

Vitamin D has been shown to suppress the growth of cancer cells. Cancer cells are believed to take up bioavailable 25-hydroxyvitamin D (25[OH]D) (i.e., not bound to vitamin-D-binding protein (DBP)) more efficiently than DBP-bound 25(OH)D. Our aim was to use this bioavailable 25(OH)D, rather than total 25(OH)D, as a biomarker of vitamin D deficiency to investigate whether vitamin D supplementation improves the relapse-free survival (RFS) of patients with digestive tract cancer from the esophagus to the rectum by conducting a post hoc analysis of the AMATERASU trial (UMIN000001977). The bioavailable 25(OH)D levels were calculated via an equation using data of serum total 25(OH)D, albumin, and DBP levels, and DBP genotypes (rs7041 and rs4588). We estimated bioavailable 25(OH) levels in 355 patients. In a subgroup of patients with low bioavailable 25(OH)D levels (<median) (n = 177), 5 year RFS was 77% in the vitamin D group vs. 58% in the placebo group (hazard ratio, 0.54; 95% confidence interval, 0.31–0.95; p = 0.03), whereas no significant difference was seen in a subgroup of patients with high bioavailable 25(OH)D levels (p for interaction = 0.046). We hypothesize that vitamin D supplementation may be effective in improving RFS among digestive tract cancer patients with low bioavailable 25(OH)D levels.

scholarly journals Perioperative Factors Related to Survival Period after Discharge of Postoperative Digestive Tract Cancer Patients

2019 ◽  
Vol 34 (1) ◽  
pp. 7-12
Author(s):  
Motomitsu NAKAE ◽  
Naoki AKADA ◽  
Hirokazu SE ◽  
Tomoya YAMAMOTO ◽  
Jyuichi KAWAKAMI
Keyword(s):  
Cancer Patients ◽  
Digestive Tract ◽  
Survival Period ◽  
Digestive Tract Cancer ◽  
Tract Cancer

scholarly journals Prevalence of diabetes mellitus among 80,193 gastrointestinal cancer patients in five European and three Asian countries

2021 ◽  
Author(s):  
Christoph Roderburg ◽  
Sven H. Loosen ◽  
Laura Hoyer ◽  
Tom Luedde ◽  
Karel Kostev
Keyword(s):  
Diabetes Mellitus ◽  
Cancer Patients ◽  
Digestive Tract ◽  
Cancer Site ◽  
Asian Countries ◽  
Rectum Cancer ◽  
Digestive Tract Cancer ◽  
Tract Cancer ◽  
High Prevalence ◽  
Prevalence Of Diabetes Mellitus

Abstract Background Diabetes mellitus (DM) has recently been associated with an increased incidence of such digestive tract malignancies as gastric or colorectal cancer. However, systematic data on the prevalence of DM among digestive tract cancer entities, especially in terms of geographic distributions, are lacking. Methods We used the Oncology Dynamics database (IQVIA) to identify a total of 80,193 patients with gastrointestinal (GI) cancer (5845 esophagus, 20,806 stomach, 38,138 colon, and 15,414 rectum cancer patients) from eight European and Asian countries. Results The overall prevalence of DM among all digestive tract cancer patients was 14.8% (11,866/80,193). In terms of cancer site, DM prevalence was highest in patients with colon (15.5%) or rectal (15.3%) cancer and lowest in patients with esophageal cancer (12.0%). Interestingly, we observed significant differences in DM prevalence between countries. Spain (27.8%, 31.3%) and South Korea (21.0%, 27.9%) had the highest prevalence of DM among gastric and colon cancer patients, while DM prevalence in esophageal (18.8%) and rectal (38.0%) cancer patients was highest in Germany. Conclusion Our data revealed a high prevalence of DM among digestive tract cancer patients in Europe and Asia, and showed that DM prevalence varies among digestive tract cancer sites as well as countries.

Sign in / Sign up

Export Citation Format

Share Document